You are here

  • Home
  • Archive
  • Volume 71, Issue 4
  • Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study

Citation Tools

Article menu
Download PDFPDF
Clinical and epidemiological research
Concise report
Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Gül A, Tugal-Tutkun I, Dinarello CA, et al
Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study
Annals of the Rheumatic Diseases 2012;71:563-566.